Forte Biosciences (FBRX) EBIT (2016 - 2026)
Forte Biosciences' (FBRX) quarterly EBIT came in at -$22.4 million in Q1 2026, down 39.17% year-on-year from -$36.9 million in Q1 2025, and up 8.68% on a QoQ basis from -$24.6 million in Q4 2025.
Forte Biosciences (FBRX) EBIT (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of EBIT data on file, last reported at -$22.4 million in Q1 2026.
- On a quarterly basis, EBIT fell 39.17% year-over-year to -$22.4 million in Q1 2026; TTM through Mar 2026 was -$77.0 million, a 71.35% decrease from a year earlier, with the FY2025 full-year figure at -$70.7 million, down 93.04% from the prior year.
- EBIT for Q1 2026 stood at -$22.4 million, up from -$24.6 million in the prior quarter.
- Over the last five years, EBIT for FBRX reached as high as -$2.5 million in Q1 2022 and fell as low as -$24.6 million in Q4 2025.
- Historically, EBIT has averaged -$10.4 million across 5 years, with a median of -$8.6 million in 2024.
- Across the five-year window, EBIT surged 55.54% in 2022 and sank 234.25% in 2025, its largest moves.
- Year by year, EBIT stood at -$4.9 million in 2022, then fell by 29.2% to -$6.4 million in 2023, then declined by 15.2% to -$7.4 million in 2024, then sank by 234.25% to -$24.6 million in 2025, then grew by 8.68% to -$22.4 million in 2026.
- Per Business Quant data, the three most recent EBIT figures were -$22.4 million in Q1 2026, -$24.6 million in Q4 2025, and -$18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Forte Biosciences | 994.79 Mn | 936.59 Mn | - | -22.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.44 Mn |
| Dec 31, 2025 | -24.57 Mn |
| Sep 30, 2025 | -18.38 Mn |
| Jun 30, 2025 | -11.58 Mn |
| Mar 31, 2025 | -16.12 Mn |
| Dec 31, 2024 | -7.35 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Jun 30, 2024 | -12.82 Mn |
| Mar 31, 2024 | -7.80 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.03 Mn |
| Mar 31, 2023 | -6.86 Mn |
| Dec 31, 2022 | -4.94 Mn |
| Sep 30, 2022 | -3.42 Mn |
| Jun 30, 2022 | -3.02 Mn |
| Mar 31, 2022 | -2.51 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Sep 30, 2021 | -7.70 Mn |
| Jun 30, 2021 | -5.75 Mn |